<TEXT>&#2;<DATELINE>2018-02-01</DATELINE><TITLE>Repurposing of Kinase Inhibitors as Broad-Spectrum Antiviral Drugs</TITLE><BODY>The high cost of drug development and the narrow spectrum of coverage typically provided by direct-acting antivirals limit the scalability of this antiviral approach. This review summarizes progress and challenges in the repurposing of approved kinase inhibitors as host-targeted broad-spectrum antiviral therapies.&#3;</BODY></TEXT>